nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketoprofen—PTGS2—skin cancer	0.318	1	CbGaD
Ketoprofen—ALB—Vismodegib—skin cancer	0.0745	0.151	CbGbCtD
Ketoprofen—SLC22A7—Fluorouracil—skin cancer	0.073	0.148	CbGbCtD
Ketoprofen—ABCC4—Fluorouracil—skin cancer	0.0713	0.145	CbGbCtD
Ketoprofen—ALB—Vemurafenib—skin cancer	0.0589	0.12	CbGbCtD
Ketoprofen—CYP2C8—Vismodegib—skin cancer	0.0575	0.117	CbGbCtD
Ketoprofen—SLC22A7—Docetaxel—skin cancer	0.0558	0.113	CbGbCtD
Ketoprofen—CYP2C9—Vismodegib—skin cancer	0.0401	0.0815	CbGbCtD
Ketoprofen—ALB—Fluorouracil—skin cancer	0.0264	0.0537	CbGbCtD
Ketoprofen—CYP2C8—Fluorouracil—skin cancer	0.0204	0.0415	CbGbCtD
Ketoprofen—CYP2C9—Fluorouracil—skin cancer	0.0143	0.029	CbGbCtD
Ketoprofen—CXCL8—nipple—skin cancer	0.00105	0.0935	CbGeAlD
Ketoprofen—PTGS2—leg—skin cancer	0.000902	0.0804	CbGeAlD
Ketoprofen—CXCR1—lymph node—skin cancer	0.000865	0.0771	CbGeAlD
Ketoprofen—PTGS2—hindlimb—skin cancer	0.000806	0.0718	CbGeAlD
Ketoprofen—PTGS2—appendage—skin cancer	0.000691	0.0616	CbGeAlD
Ketoprofen—PTGS2—skin epidermis—skin cancer	0.000575	0.0512	CbGeAlD
Ketoprofen—CXCR1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000515	0.0132	CbGpPWpGaD
Ketoprofen—Ketorolac—PTGS2—skin cancer	0.000506	0.109	CrCbGaD
Ketoprofen—Carprofen—PTGS2—skin cancer	0.000506	0.109	CrCbGaD
Ketoprofen—Bromfenac—PTGS2—skin cancer	0.000486	0.105	CrCbGaD
Ketoprofen—SLC22A7—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000485	0.0124	CbGpPWpGaD
Ketoprofen—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.000472	0.0121	CbGpPWpGaD
Ketoprofen—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—skin cancer	0.000471	0.0121	CbGpPWpGaD
Ketoprofen—CXCL8—Overview of nanoparticle effects—PTGS2—skin cancer	0.000465	0.0119	CbGpPWpGaD
Ketoprofen—CXCR1—GPCR ligand binding—PTCH2—skin cancer	0.000465	0.0119	CbGpPWpGaD
Ketoprofen—CXCL8—Spinal Cord Injury—CSPG4—skin cancer	0.000456	0.0117	CbGpPWpGaD
Ketoprofen—CXCR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000442	0.0113	CbGpPWpGaD
Ketoprofen—CXCL8—Bladder Cancer—CDK4—skin cancer	0.00044	0.0113	CbGpPWpGaD
Ketoprofen—PTGS1—endothelium—skin cancer	0.000436	0.0389	CbGeAlD
Ketoprofen—SLC22A11—female reproductive system—skin cancer	0.000435	0.0387	CbGeAlD
Ketoprofen—CXCL8—Regulation of toll-like receptor signaling pathway—TLR7—skin cancer	0.00043	0.011	CbGpPWpGaD
Ketoprofen—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000418	0.0107	CbGpPWpGaD
Ketoprofen—PTGS2—endothelium—skin cancer	0.000417	0.0372	CbGeAlD
Ketoprofen—Tiaprofenic acid—PTGS2—skin cancer	0.000413	0.0889	CrCbGaD
Ketoprofen—PTGS1—blood vessel—skin cancer	0.000403	0.0359	CbGeAlD
Ketoprofen—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.0004	0.0102	CbGpPWpGaD
Ketoprofen—Nepafenac—PTGS2—skin cancer	0.000393	0.0846	CrCbGaD
Ketoprofen—ABCC4—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000391	0.01	CbGpPWpGaD
Ketoprofen—CXCL8—Bladder Cancer—BRAF—skin cancer	0.000389	0.00997	CbGpPWpGaD
Ketoprofen—PTGS2—blood vessel—skin cancer	0.000385	0.0343	CbGeAlD
Ketoprofen—Magnesium salicylate—PTGS2—skin cancer	0.000384	0.0827	CrCbGaD
Ketoprofen—Fenbufen—PTGS2—skin cancer	0.000376	0.0809	CrCbGaD
Ketoprofen—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.000375	0.0096	CbGpPWpGaD
Ketoprofen—CXCR1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000339	0.00868	CbGpPWpGaD
Ketoprofen—CXCL8—Bladder Cancer—CDKN2A—skin cancer	0.000336	0.00861	CbGpPWpGaD
Ketoprofen—CXCR1—GPCR ligand binding—MC1R—skin cancer	0.000336	0.00861	CbGpPWpGaD
Ketoprofen—Paraesthesia—Imiquimod—skin cancer	0.000329	0.00245	CcSEcCtD
Ketoprofen—Chills—Bleomycin—skin cancer	0.000329	0.00244	CcSEcCtD
Ketoprofen—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—skin cancer	0.000328	0.00839	CbGpPWpGaD
Ketoprofen—Cardiac failure congestive—Docetaxel—skin cancer	0.000328	0.00243	CcSEcCtD
Ketoprofen—Dyspnoea—Imiquimod—skin cancer	0.000327	0.00243	CcSEcCtD
Ketoprofen—Salsalate—PTGS2—skin cancer	0.000326	0.0703	CrCbGaD
Ketoprofen—Somnolence—Imiquimod—skin cancer	0.000326	0.00242	CcSEcCtD
Ketoprofen—Photosensitivity reaction—Fluorouracil—skin cancer	0.000325	0.00241	CcSEcCtD
Ketoprofen—Alopecia—Bleomycin—skin cancer	0.000324	0.00241	CcSEcCtD
Ketoprofen—Erythema multiforme—Dactinomycin—skin cancer	0.000323	0.0024	CcSEcCtD
Ketoprofen—Dyspepsia—Imiquimod—skin cancer	0.000323	0.0024	CcSEcCtD
Ketoprofen—Erythema—Bleomycin—skin cancer	0.000319	0.00237	CcSEcCtD
Ketoprofen—Decreased appetite—Imiquimod—skin cancer	0.000319	0.00237	CcSEcCtD
Ketoprofen—Flushing—Dactinomycin—skin cancer	0.000317	0.00236	CcSEcCtD
Ketoprofen—Hypersensitivity—Vemurafenib—skin cancer	0.000317	0.00235	CcSEcCtD
Ketoprofen—Gastrointestinal disorder—Imiquimod—skin cancer	0.000316	0.00235	CcSEcCtD
Ketoprofen—Fatigue—Imiquimod—skin cancer	0.000316	0.00235	CcSEcCtD
Ketoprofen—Visual disturbance—Docetaxel—skin cancer	0.000314	0.00233	CcSEcCtD
Ketoprofen—Suprofen—PTGS2—skin cancer	0.000313	0.0674	CrCbGaD
Ketoprofen—Acute coronary syndrome—Fluorouracil—skin cancer	0.000313	0.00232	CcSEcCtD
Ketoprofen—Renal impairment—Docetaxel—skin cancer	0.000312	0.00232	CcSEcCtD
Ketoprofen—Myocardial infarction—Fluorouracil—skin cancer	0.000311	0.00231	CcSEcCtD
Ketoprofen—Dermatitis bullous—Docetaxel—skin cancer	0.000311	0.00231	CcSEcCtD
Ketoprofen—Stomatitis—Fluorouracil—skin cancer	0.000309	0.0023	CcSEcCtD
Ketoprofen—Hepatitis—Temozolomide—skin cancer	0.000309	0.0023	CcSEcCtD
Ketoprofen—Conjunctivitis—Fluorouracil—skin cancer	0.000308	0.00229	CcSEcCtD
Ketoprofen—Asthenia—Vemurafenib—skin cancer	0.000308	0.00229	CcSEcCtD
Ketoprofen—Hallucination—Temozolomide—skin cancer	0.000308	0.00229	CcSEcCtD
Ketoprofen—CXCL8—lymph node—skin cancer	0.000307	0.0274	CbGeAlD
Ketoprofen—Pharyngitis—Temozolomide—skin cancer	0.000307	0.00228	CcSEcCtD
Ketoprofen—Chills—Dactinomycin—skin cancer	0.000307	0.00228	CcSEcCtD
Ketoprofen—SLC22A11—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000305	0.00782	CbGpPWpGaD
Ketoprofen—Cardiac failure—Docetaxel—skin cancer	0.000304	0.00226	CcSEcCtD
Ketoprofen—Pruritus—Vemurafenib—skin cancer	0.000304	0.00226	CcSEcCtD
Ketoprofen—Alopecia—Dactinomycin—skin cancer	0.000302	0.00224	CcSEcCtD
Ketoprofen—Feeling abnormal—Imiquimod—skin cancer	0.000302	0.00224	CcSEcCtD
Ketoprofen—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—skin cancer	0.0003	0.00769	CbGpPWpGaD
Ketoprofen—Gastrointestinal pain—Imiquimod—skin cancer	0.0003	0.00223	CcSEcCtD
Ketoprofen—Epistaxis—Fluorouracil—skin cancer	0.000299	0.00222	CcSEcCtD
Ketoprofen—Hyponatraemia—Docetaxel—skin cancer	0.000298	0.00222	CcSEcCtD
Ketoprofen—Visual impairment—Temozolomide—skin cancer	0.000298	0.00221	CcSEcCtD
Ketoprofen—Erythema—Dactinomycin—skin cancer	0.000298	0.00221	CcSEcCtD
Ketoprofen—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000297	0.00221	CcSEcCtD
Ketoprofen—CXCL8—Peptide ligand-binding receptors—MC1R—skin cancer	0.000297	0.00761	CbGpPWpGaD
Ketoprofen—Agranulocytosis—Fluorouracil—skin cancer	0.000296	0.0022	CcSEcCtD
Ketoprofen—Ill-defined disorder—Bleomycin—skin cancer	0.000296	0.0022	CcSEcCtD
Ketoprofen—Anaemia—Bleomycin—skin cancer	0.000295	0.00219	CcSEcCtD
Ketoprofen—Diarrhoea—Vemurafenib—skin cancer	0.000294	0.00218	CcSEcCtD
Ketoprofen—Migraine—Docetaxel—skin cancer	0.000292	0.00217	CcSEcCtD
Ketoprofen—Erythema multiforme—Temozolomide—skin cancer	0.000292	0.00217	CcSEcCtD
Ketoprofen—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—skin cancer	0.000292	0.00748	CbGpPWpGaD
Ketoprofen—Urticaria—Imiquimod—skin cancer	0.000291	0.00216	CcSEcCtD
Ketoprofen—PTGS1—nipple—skin cancer	0.000291	0.0259	CbGeAlD
Ketoprofen—CXCR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00029	0.00744	CbGpPWpGaD
Ketoprofen—Abdominal pain—Imiquimod—skin cancer	0.00029	0.00215	CcSEcCtD
Ketoprofen—CXCR1—Signaling Pathways—RHOU—skin cancer	0.000289	0.00739	CbGpPWpGaD
Ketoprofen—Tinnitus—Temozolomide—skin cancer	0.000288	0.00214	CcSEcCtD
Ketoprofen—Malaise—Bleomycin—skin cancer	0.000288	0.00214	CcSEcCtD
Ketoprofen—Flushing—Temozolomide—skin cancer	0.000287	0.00213	CcSEcCtD
Ketoprofen—Rhinitis—Fluorouracil—skin cancer	0.000286	0.00212	CcSEcCtD
Ketoprofen—Dizziness—Vemurafenib—skin cancer	0.000284	0.00211	CcSEcCtD
Ketoprofen—Pharyngitis—Fluorouracil—skin cancer	0.000283	0.0021	CcSEcCtD
Ketoprofen—Chills—Temozolomide—skin cancer	0.000277	0.00206	CcSEcCtD
Ketoprofen—SLC22A7—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000277	0.00709	CbGpPWpGaD
Ketoprofen—Ill-defined disorder—Dactinomycin—skin cancer	0.000276	0.00205	CcSEcCtD
Ketoprofen—Anaemia—Dactinomycin—skin cancer	0.000275	0.00204	CcSEcCtD
Ketoprofen—Vomiting—Vemurafenib—skin cancer	0.000273	0.00203	CcSEcCtD
Ketoprofen—Alopecia—Temozolomide—skin cancer	0.000273	0.00203	CcSEcCtD
Ketoprofen—Myalgia—Bleomycin—skin cancer	0.000272	0.00202	CcSEcCtD
Ketoprofen—Abdominal pain upper—Docetaxel—skin cancer	0.000271	0.00202	CcSEcCtD
Ketoprofen—Rash—Vemurafenib—skin cancer	0.000271	0.00201	CcSEcCtD
Ketoprofen—Dermatitis—Vemurafenib—skin cancer	0.000271	0.00201	CcSEcCtD
Ketoprofen—Hypersensitivity—Imiquimod—skin cancer	0.00027	0.00201	CcSEcCtD
Ketoprofen—Fenoprofen—PTGS2—skin cancer	0.00027	0.0581	CrCbGaD
Ketoprofen—Headache—Vemurafenib—skin cancer	0.000269	0.002	CcSEcCtD
Ketoprofen—Erythema—Temozolomide—skin cancer	0.000269	0.002	CcSEcCtD
Ketoprofen—Discomfort—Bleomycin—skin cancer	0.000268	0.00199	CcSEcCtD
Ketoprofen—Malaise—Dactinomycin—skin cancer	0.000268	0.00199	CcSEcCtD
Ketoprofen—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000268	0.00199	CcSEcCtD
Ketoprofen—CXCR1—Differentiation Pathway—IL6—skin cancer	0.000268	0.00685	CbGpPWpGaD
Ketoprofen—Dysgeusia—Temozolomide—skin cancer	0.000264	0.00196	CcSEcCtD
Ketoprofen—Asthenia—Imiquimod—skin cancer	0.000263	0.00195	CcSEcCtD
Ketoprofen—CXCL8—ATF-2 transcription factor network—CDK4—skin cancer	0.000263	0.00673	CbGpPWpGaD
Ketoprofen—Confusional state—Bleomycin—skin cancer	0.000263	0.00195	CcSEcCtD
Ketoprofen—Anaphylactic shock—Bleomycin—skin cancer	0.00026	0.00193	CcSEcCtD
Ketoprofen—Oedema—Bleomycin—skin cancer	0.00026	0.00193	CcSEcCtD
Ketoprofen—Pruritus—Imiquimod—skin cancer	0.000259	0.00193	CcSEcCtD
Ketoprofen—Infection—Bleomycin—skin cancer	0.000259	0.00192	CcSEcCtD
Ketoprofen—PTGS1—Overview of nanoparticle effects—PTGS2—skin cancer	0.000257	0.00657	CbGpPWpGaD
Ketoprofen—Nausea—Vemurafenib—skin cancer	0.000255	0.0019	CcSEcCtD
Ketoprofen—Thrombocytopenia—Bleomycin—skin cancer	0.000255	0.00189	CcSEcCtD
Ketoprofen—Arrhythmia—Fluorouracil—skin cancer	0.000254	0.00189	CcSEcCtD
Ketoprofen—CXCL8—Overview of nanoparticle effects—IL6—skin cancer	0.000253	0.00649	CbGpPWpGaD
Ketoprofen—Myalgia—Dactinomycin—skin cancer	0.000253	0.00188	CcSEcCtD
Ketoprofen—Bronchospasm—Docetaxel—skin cancer	0.000253	0.00188	CcSEcCtD
Ketoprofen—Alopecia—Fluorouracil—skin cancer	0.000252	0.00187	CcSEcCtD
Ketoprofen—Diarrhoea—Imiquimod—skin cancer	0.000251	0.00186	CcSEcCtD
Ketoprofen—Discomfort—Dactinomycin—skin cancer	0.00025	0.00186	CcSEcCtD
Ketoprofen—Mefenamic acid—PTGS2—skin cancer	0.00025	0.0539	CrCbGaD
Ketoprofen—Ill-defined disorder—Temozolomide—skin cancer	0.00025	0.00186	CcSEcCtD
Ketoprofen—Anaemia—Temozolomide—skin cancer	0.000249	0.00185	CcSEcCtD
Ketoprofen—Anorexia—Bleomycin—skin cancer	0.000248	0.00184	CcSEcCtD
Ketoprofen—Erythema—Fluorouracil—skin cancer	0.000248	0.00184	CcSEcCtD
Ketoprofen—ABCC4—female reproductive system—skin cancer	0.000247	0.022	CbGeAlD
Ketoprofen—Angioedema—Temozolomide—skin cancer	0.000246	0.00183	CcSEcCtD
Ketoprofen—Naproxen—PTGS2—skin cancer	0.000246	0.0529	CrCbGaD
Ketoprofen—Oedema—Dactinomycin—skin cancer	0.000243	0.0018	CcSEcCtD
Ketoprofen—Malaise—Temozolomide—skin cancer	0.000243	0.0018	CcSEcCtD
Ketoprofen—Dizziness—Imiquimod—skin cancer	0.000242	0.0018	CcSEcCtD
Ketoprofen—Vertigo—Temozolomide—skin cancer	0.000242	0.0018	CcSEcCtD
Ketoprofen—Infection—Dactinomycin—skin cancer	0.000241	0.00179	CcSEcCtD
Ketoprofen—CXCR1—GPCR ligand binding—SHH—skin cancer	0.00024	0.00614	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—PTCH2—skin cancer	0.000239	0.00611	CbGpPWpGaD
Ketoprofen—Palpitations—Temozolomide—skin cancer	0.000238	0.00177	CcSEcCtD
Ketoprofen—Thrombocytopenia—Dactinomycin—skin cancer	0.000238	0.00177	CcSEcCtD
Ketoprofen—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000237	0.00176	CcSEcCtD
Ketoprofen—Paraesthesia—Bleomycin—skin cancer	0.000234	0.00174	CcSEcCtD
Ketoprofen—Weight increased—Docetaxel—skin cancer	0.000234	0.00174	CcSEcCtD
Ketoprofen—Convulsion—Temozolomide—skin cancer	0.000233	0.00173	CcSEcCtD
Ketoprofen—Vomiting—Imiquimod—skin cancer	0.000233	0.00173	CcSEcCtD
Ketoprofen—SLC22A8—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000233	0.00596	CbGpPWpGaD
Ketoprofen—Weight decreased—Docetaxel—skin cancer	0.000232	0.00173	CcSEcCtD
Ketoprofen—Hypertension—Temozolomide—skin cancer	0.000232	0.00173	CcSEcCtD
Ketoprofen—Dyspnoea—Bleomycin—skin cancer	0.000232	0.00172	CcSEcCtD
Ketoprofen—Anorexia—Dactinomycin—skin cancer	0.000231	0.00172	CcSEcCtD
Ketoprofen—Rash—Imiquimod—skin cancer	0.000231	0.00172	CcSEcCtD
Ketoprofen—Dermatitis—Imiquimod—skin cancer	0.000231	0.00172	CcSEcCtD
Ketoprofen—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—skin cancer	0.00023	0.0059	CbGpPWpGaD
Ketoprofen—Headache—Imiquimod—skin cancer	0.00023	0.00171	CcSEcCtD
Ketoprofen—Anaemia—Fluorouracil—skin cancer	0.000229	0.0017	CcSEcCtD
Ketoprofen—Myalgia—Temozolomide—skin cancer	0.000229	0.0017	CcSEcCtD
Ketoprofen—Anxiety—Temozolomide—skin cancer	0.000228	0.0017	CcSEcCtD
Ketoprofen—CXCR1—GPCR ligand binding—PTCH1—skin cancer	0.000227	0.00582	CbGpPWpGaD
Ketoprofen—CXCR1—GPCR ligand binding—SMO—skin cancer	0.000227	0.00582	CbGpPWpGaD
Ketoprofen—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000227	0.00169	CcSEcCtD
Ketoprofen—Discomfort—Temozolomide—skin cancer	0.000226	0.00168	CcSEcCtD
Ketoprofen—Decreased appetite—Bleomycin—skin cancer	0.000226	0.00168	CcSEcCtD
Ketoprofen—Acute coronary syndrome—Docetaxel—skin cancer	0.000226	0.00168	CcSEcCtD
Ketoprofen—Renal failure—Docetaxel—skin cancer	0.000225	0.00167	CcSEcCtD
Ketoprofen—Myocardial infarction—Docetaxel—skin cancer	0.000224	0.00167	CcSEcCtD
Ketoprofen—Dry mouth—Temozolomide—skin cancer	0.000224	0.00166	CcSEcCtD
Ketoprofen—Stomatitis—Docetaxel—skin cancer	0.000223	0.00166	CcSEcCtD
Ketoprofen—Jaundice—Docetaxel—skin cancer	0.000223	0.00166	CcSEcCtD
Ketoprofen—Conjunctivitis—Docetaxel—skin cancer	0.000223	0.00165	CcSEcCtD
Ketoprofen—Confusional state—Temozolomide—skin cancer	0.000221	0.00165	CcSEcCtD
Ketoprofen—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000221	0.00164	CcSEcCtD
Ketoprofen—CXCR1—GPCR ligand binding—PTGER4—skin cancer	0.000221	0.00566	CbGpPWpGaD
Ketoprofen—Oedema—Temozolomide—skin cancer	0.00022	0.00163	CcSEcCtD
Ketoprofen—Anaphylactic shock—Temozolomide—skin cancer	0.00022	0.00163	CcSEcCtD
Ketoprofen—Infection—Temozolomide—skin cancer	0.000218	0.00162	CcSEcCtD
Ketoprofen—Nausea—Imiquimod—skin cancer	0.000218	0.00162	CcSEcCtD
Ketoprofen—Epistaxis—Docetaxel—skin cancer	0.000216	0.0016	CcSEcCtD
Ketoprofen—Thrombocytopenia—Temozolomide—skin cancer	0.000215	0.0016	CcSEcCtD
Ketoprofen—Convulsion—Fluorouracil—skin cancer	0.000215	0.0016	CcSEcCtD
Ketoprofen—SLCO1A2—head—skin cancer	0.000215	0.0191	CbGeAlD
Ketoprofen—Feeling abnormal—Bleomycin—skin cancer	0.000215	0.00159	CcSEcCtD
Ketoprofen—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—skin cancer	0.000215	0.00549	CbGpPWpGaD
Ketoprofen—ABCC4—Ectoderm Differentiation—SHH—skin cancer	0.000214	0.00548	CbGpPWpGaD
Ketoprofen—Agranulocytosis—Docetaxel—skin cancer	0.000214	0.00159	CcSEcCtD
Ketoprofen—PTGS1—Eicosanoid Synthesis—PTGS2—skin cancer	0.000213	0.00545	CbGpPWpGaD
Ketoprofen—Hyperhidrosis—Temozolomide—skin cancer	0.000212	0.00158	CcSEcCtD
Ketoprofen—Myalgia—Fluorouracil—skin cancer	0.000211	0.00157	CcSEcCtD
Ketoprofen—Decreased appetite—Dactinomycin—skin cancer	0.000211	0.00157	CcSEcCtD
Ketoprofen—CXCL8—GPCR ligand binding—PTCH2—skin cancer	0.00021	0.00538	CbGpPWpGaD
Ketoprofen—Fatigue—Dactinomycin—skin cancer	0.000209	0.00156	CcSEcCtD
Ketoprofen—Anorexia—Temozolomide—skin cancer	0.000209	0.00156	CcSEcCtD
Ketoprofen—Discomfort—Fluorouracil—skin cancer	0.000209	0.00155	CcSEcCtD
Ketoprofen—Urticaria—Bleomycin—skin cancer	0.000207	0.00154	CcSEcCtD
Ketoprofen—SLCO1A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000207	0.00529	CbGpPWpGaD
Ketoprofen—ABCC4—head—skin cancer	0.000207	0.0184	CbGeAlD
Ketoprofen—PTGS1—connective tissue—skin cancer	0.000206	0.0184	CbGeAlD
Ketoprofen—Rhinitis—Docetaxel—skin cancer	0.000206	0.00153	CcSEcCtD
Ketoprofen—Hepatitis—Docetaxel—skin cancer	0.000206	0.00153	CcSEcCtD
Ketoprofen—SLC22A8—head—skin cancer	0.000205	0.0183	CbGeAlD
Ketoprofen—Confusional state—Fluorouracil—skin cancer	0.000204	0.00152	CcSEcCtD
Ketoprofen—Pharyngitis—Docetaxel—skin cancer	0.000204	0.00152	CcSEcCtD
Ketoprofen—Anaphylactic shock—Fluorouracil—skin cancer	0.000202	0.0015	CcSEcCtD
Ketoprofen—Oedema—Fluorouracil—skin cancer	0.000202	0.0015	CcSEcCtD
Ketoprofen—Infection—Fluorouracil—skin cancer	0.000201	0.00149	CcSEcCtD
Ketoprofen—Feeling abnormal—Dactinomycin—skin cancer	0.0002	0.00149	CcSEcCtD
Ketoprofen—Musculoskeletal discomfort—Temozolomide—skin cancer	0.0002	0.00149	CcSEcCtD
Ketoprofen—PTGS2—Spinal Cord Injury—CSPG4—skin cancer	0.0002	0.00511	CbGpPWpGaD
Ketoprofen—CXCL8—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000199	0.0051	CbGpPWpGaD
Ketoprofen—Insomnia—Temozolomide—skin cancer	0.000199	0.00148	CcSEcCtD
Ketoprofen—Gastrointestinal pain—Dactinomycin—skin cancer	0.000199	0.00148	CcSEcCtD
Ketoprofen—Thrombocytopenia—Fluorouracil—skin cancer	0.000198	0.00147	CcSEcCtD
Ketoprofen—Visual impairment—Docetaxel—skin cancer	0.000198	0.00147	CcSEcCtD
Ketoprofen—Tachycardia—Fluorouracil—skin cancer	0.000197	0.00147	CcSEcCtD
Ketoprofen—PTGS2—connective tissue—skin cancer	0.000197	0.0176	CbGeAlD
Ketoprofen—Paraesthesia—Temozolomide—skin cancer	0.000197	0.00147	CcSEcCtD
Ketoprofen—PTGS1—epithelium—skin cancer	0.000196	0.0175	CbGeAlD
Ketoprofen—Dyspnoea—Temozolomide—skin cancer	0.000196	0.00145	CcSEcCtD
Ketoprofen—Somnolence—Temozolomide—skin cancer	0.000195	0.00145	CcSEcCtD
Ketoprofen—Erythema multiforme—Docetaxel—skin cancer	0.000194	0.00144	CcSEcCtD
Ketoprofen—SLC22A6—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000194	0.00498	CbGpPWpGaD
Ketoprofen—Dyspepsia—Temozolomide—skin cancer	0.000193	0.00144	CcSEcCtD
Ketoprofen—Anorexia—Fluorouracil—skin cancer	0.000193	0.00143	CcSEcCtD
Ketoprofen—Abdominal pain—Dactinomycin—skin cancer	0.000192	0.00143	CcSEcCtD
Ketoprofen—Hypersensitivity—Bleomycin—skin cancer	0.000192	0.00143	CcSEcCtD
Ketoprofen—Decreased appetite—Temozolomide—skin cancer	0.000191	0.00142	CcSEcCtD
Ketoprofen—Flushing—Docetaxel—skin cancer	0.000191	0.00142	CcSEcCtD
Ketoprofen—CXCR1—GPCR downstream signaling—MC1R—skin cancer	0.00019	0.00487	CbGpPWpGaD
Ketoprofen—Gastrointestinal disorder—Temozolomide—skin cancer	0.00019	0.00141	CcSEcCtD
Ketoprofen—Fatigue—Temozolomide—skin cancer	0.000189	0.00141	CcSEcCtD
Ketoprofen—Constipation—Temozolomide—skin cancer	0.000188	0.0014	CcSEcCtD
Ketoprofen—PTGS2—epithelium—skin cancer	0.000187	0.0167	CbGeAlD
Ketoprofen—CXCL8—Bladder Cancer—TP53—skin cancer	0.000187	0.00479	CbGpPWpGaD
Ketoprofen—Asthenia—Bleomycin—skin cancer	0.000187	0.00139	CcSEcCtD
Ketoprofen—PTGS1—skin of body—skin cancer	0.000186	0.0166	CbGeAlD
Ketoprofen—Chills—Docetaxel—skin cancer	0.000184	0.00137	CcSEcCtD
Ketoprofen—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000184	0.00137	CcSEcCtD
Ketoprofen—Pruritus—Bleomycin—skin cancer	0.000184	0.00137	CcSEcCtD
Ketoprofen—Arrhythmia—Docetaxel—skin cancer	0.000184	0.00136	CcSEcCtD
Ketoprofen—Insomnia—Fluorouracil—skin cancer	0.000183	0.00136	CcSEcCtD
Ketoprofen—Paraesthesia—Fluorouracil—skin cancer	0.000182	0.00135	CcSEcCtD
Ketoprofen—Alopecia—Docetaxel—skin cancer	0.000182	0.00135	CcSEcCtD
Ketoprofen—Feeling abnormal—Temozolomide—skin cancer	0.000181	0.00134	CcSEcCtD
Ketoprofen—Dyspnoea—Fluorouracil—skin cancer	0.00018	0.00134	CcSEcCtD
Ketoprofen—Somnolence—Fluorouracil—skin cancer	0.00018	0.00134	CcSEcCtD
Ketoprofen—Gastrointestinal pain—Temozolomide—skin cancer	0.00018	0.00133	CcSEcCtD
Ketoprofen—CYP2C8—female reproductive system—skin cancer	0.000179	0.016	CbGeAlD
Ketoprofen—CXCL8—Bladder Cancer—HRAS—skin cancer	0.000179	0.00458	CbGpPWpGaD
Ketoprofen—Erythema—Docetaxel—skin cancer	0.000179	0.00133	CcSEcCtD
Ketoprofen—Hypersensitivity—Dactinomycin—skin cancer	0.000179	0.00133	CcSEcCtD
Ketoprofen—PTGS2—skin of body—skin cancer	0.000178	0.0159	CbGeAlD
Ketoprofen—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.000178	0.00456	CbGpPWpGaD
Ketoprofen—Dyspepsia—Fluorouracil—skin cancer	0.000178	0.00132	CcSEcCtD
Ketoprofen—Flurbiprofen—PTGS2—skin cancer	0.000176	0.0379	CrCbGaD
Ketoprofen—Decreased appetite—Fluorouracil—skin cancer	0.000176	0.00131	CcSEcCtD
Ketoprofen—CXCL8—AP-1 transcription factor network—CDKN2A—skin cancer	0.000175	0.00449	CbGpPWpGaD
Ketoprofen—Dysgeusia—Docetaxel—skin cancer	0.000175	0.0013	CcSEcCtD
Ketoprofen—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000175	0.0013	CcSEcCtD
Ketoprofen—Urticaria—Temozolomide—skin cancer	0.000174	0.0013	CcSEcCtD
Ketoprofen—Asthenia—Dactinomycin—skin cancer	0.000174	0.00129	CcSEcCtD
Ketoprofen—CXCL8—Metabolism of proteins—EXOC2—skin cancer	0.000174	0.00445	CbGpPWpGaD
Ketoprofen—Abdominal pain—Temozolomide—skin cancer	0.000174	0.00129	CcSEcCtD
Ketoprofen—SLC22A7—Fluoropyrimidine Activity—TP53—skin cancer	0.000173	0.00443	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—MC1R—skin cancer	0.000173	0.00442	CbGpPWpGaD
Ketoprofen—PTGS1—mammalian vulva—skin cancer	0.00017	0.0151	CbGeAlD
Ketoprofen—Feeling abnormal—Fluorouracil—skin cancer	0.000167	0.00124	CcSEcCtD
Ketoprofen—Diarrhoea—Dactinomycin—skin cancer	0.000166	0.00123	CcSEcCtD
Ketoprofen—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—CDK4—skin cancer	0.000166	0.00425	CbGpPWpGaD
Ketoprofen—Vomiting—Bleomycin—skin cancer	0.000166	0.00123	CcSEcCtD
Ketoprofen—Anaemia—Docetaxel—skin cancer	0.000165	0.00123	CcSEcCtD
Ketoprofen—Rash—Bleomycin—skin cancer	0.000164	0.00122	CcSEcCtD
Ketoprofen—Dermatitis—Bleomycin—skin cancer	0.000164	0.00122	CcSEcCtD
Ketoprofen—CXCL8—Corticotropin-releasing hormone—BRAF—skin cancer	0.000163	0.00418	CbGpPWpGaD
Ketoprofen—Hypersensitivity—Temozolomide—skin cancer	0.000162	0.0012	CcSEcCtD
Ketoprofen—Urticaria—Fluorouracil—skin cancer	0.000161	0.00119	CcSEcCtD
Ketoprofen—CYP2C9—female reproductive system—skin cancer	0.000159	0.0142	CbGeAlD
Ketoprofen—CXCL8—Syndecan-2-mediated signaling events—HRAS—skin cancer	0.000159	0.00407	CbGpPWpGaD
Ketoprofen—Palpitations—Docetaxel—skin cancer	0.000158	0.00118	CcSEcCtD
Ketoprofen—Asthenia—Temozolomide—skin cancer	0.000158	0.00117	CcSEcCtD
Ketoprofen—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—skin cancer	0.000158	0.00403	CbGpPWpGaD
Ketoprofen—Pruritus—Temozolomide—skin cancer	0.000155	0.00115	CcSEcCtD
Ketoprofen—SLC22A11—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000155	0.00397	CbGpPWpGaD
Ketoprofen—Convulsion—Docetaxel—skin cancer	0.000155	0.00115	CcSEcCtD
Ketoprofen—Nausea—Bleomycin—skin cancer	0.000155	0.00115	CcSEcCtD
Ketoprofen—Hypertension—Docetaxel—skin cancer	0.000154	0.00115	CcSEcCtD
Ketoprofen—Vomiting—Dactinomycin—skin cancer	0.000154	0.00115	CcSEcCtD
Ketoprofen—Rash—Dactinomycin—skin cancer	0.000153	0.00114	CcSEcCtD
Ketoprofen—Myalgia—Docetaxel—skin cancer	0.000152	0.00113	CcSEcCtD
Ketoprofen—CXCL8—GPCR ligand binding—MC1R—skin cancer	0.000152	0.00389	CbGpPWpGaD
Ketoprofen—CXCL8—Spinal Cord Injury—CDK4—skin cancer	0.000151	0.00387	CbGpPWpGaD
Ketoprofen—Diarrhoea—Temozolomide—skin cancer	0.00015	0.00112	CcSEcCtD
Ketoprofen—ALB—lymph node—skin cancer	0.000149	0.0133	CbGeAlD
Ketoprofen—Hypersensitivity—Fluorouracil—skin cancer	0.000149	0.00111	CcSEcCtD
Ketoprofen—Dry mouth—Docetaxel—skin cancer	0.000149	0.00111	CcSEcCtD
Ketoprofen—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—skin cancer	0.000149	0.00381	CbGpPWpGaD
Ketoprofen—Confusional state—Docetaxel—skin cancer	0.000147	0.00109	CcSEcCtD
Ketoprofen—CXCL8—Senescence and Autophagy in Cancer—BRAF—skin cancer	0.000147	0.00376	CbGpPWpGaD
Ketoprofen—Anaphylactic shock—Docetaxel—skin cancer	0.000146	0.00109	CcSEcCtD
Ketoprofen—Oedema—Docetaxel—skin cancer	0.000146	0.00109	CcSEcCtD
Ketoprofen—PTGS1—female reproductive system—skin cancer	0.000146	0.013	CbGeAlD
Ketoprofen—Dizziness—Temozolomide—skin cancer	0.000145	0.00108	CcSEcCtD
Ketoprofen—Infection—Docetaxel—skin cancer	0.000145	0.00108	CcSEcCtD
Ketoprofen—ABCC4—lymph node—skin cancer	0.000145	0.0129	CbGeAlD
Ketoprofen—PTGS2—lymphoid tissue—skin cancer	0.000144	0.0129	CbGeAlD
Ketoprofen—Nausea—Dactinomycin—skin cancer	0.000144	0.00107	CcSEcCtD
Ketoprofen—Shock—Docetaxel—skin cancer	0.000144	0.00107	CcSEcCtD
Ketoprofen—Pruritus—Fluorouracil—skin cancer	0.000143	0.00106	CcSEcCtD
Ketoprofen—Thrombocytopenia—Docetaxel—skin cancer	0.000143	0.00106	CcSEcCtD
Ketoprofen—Tachycardia—Docetaxel—skin cancer	0.000143	0.00106	CcSEcCtD
Ketoprofen—CXCR1—Signaling Pathways—PTCH2—skin cancer	0.000141	0.00361	CbGpPWpGaD
Ketoprofen—SLC22A7—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000141	0.0036	CbGpPWpGaD
Ketoprofen—PTGS1—Overview of nanoparticle effects—IL6—skin cancer	0.00014	0.00358	CbGpPWpGaD
Ketoprofen—Vomiting—Temozolomide—skin cancer	0.00014	0.00104	CcSEcCtD
Ketoprofen—ABCC4—Fluoropyrimidine Activity—TP53—skin cancer	0.000139	0.00357	CbGpPWpGaD
Ketoprofen—Anorexia—Docetaxel—skin cancer	0.000139	0.00103	CcSEcCtD
Ketoprofen—PTGS2—female reproductive system—skin cancer	0.000139	0.0124	CbGeAlD
Ketoprofen—Rash—Temozolomide—skin cancer	0.000138	0.00103	CcSEcCtD
Ketoprofen—Diarrhoea—Fluorouracil—skin cancer	0.000138	0.00103	CcSEcCtD
Ketoprofen—Dermatitis—Temozolomide—skin cancer	0.000138	0.00103	CcSEcCtD
Ketoprofen—Headache—Temozolomide—skin cancer	0.000138	0.00102	CcSEcCtD
Ketoprofen—Dizziness—Fluorouracil—skin cancer	0.000134	0.000994	CcSEcCtD
Ketoprofen—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000133	0.000989	CcSEcCtD
Ketoprofen—Insomnia—Docetaxel—skin cancer	0.000132	0.000982	CcSEcCtD
Ketoprofen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—skin cancer	0.000131	0.00337	CbGpPWpGaD
Ketoprofen—Paraesthesia—Docetaxel—skin cancer	0.000131	0.000974	CcSEcCtD
Ketoprofen—CXCL8—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000131	0.00336	CbGpPWpGaD
Ketoprofen—Nausea—Temozolomide—skin cancer	0.00013	0.000969	CcSEcCtD
Ketoprofen—CXCL8—Signaling Pathways—RHOU—skin cancer	0.00013	0.00334	CbGpPWpGaD
Ketoprofen—Dyspnoea—Docetaxel—skin cancer	0.00013	0.000967	CcSEcCtD
Ketoprofen—Somnolence—Docetaxel—skin cancer	0.00013	0.000965	CcSEcCtD
Ketoprofen—Vomiting—Fluorouracil—skin cancer	0.000129	0.000956	CcSEcCtD
Ketoprofen—Dyspepsia—Docetaxel—skin cancer	0.000129	0.000955	CcSEcCtD
Ketoprofen—Rash—Fluorouracil—skin cancer	0.000128	0.000948	CcSEcCtD
Ketoprofen—Dermatitis—Fluorouracil—skin cancer	0.000127	0.000947	CcSEcCtD
Ketoprofen—Decreased appetite—Docetaxel—skin cancer	0.000127	0.000943	CcSEcCtD
Ketoprofen—Headache—Fluorouracil—skin cancer	0.000127	0.000942	CcSEcCtD
Ketoprofen—CXCL8—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	0.000127	0.00325	CbGpPWpGaD
Ketoprofen—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—skin cancer	0.000127	0.00325	CbGpPWpGaD
Ketoprofen—Gastrointestinal disorder—Docetaxel—skin cancer	0.000126	0.000937	CcSEcCtD
Ketoprofen—Fatigue—Docetaxel—skin cancer	0.000126	0.000936	CcSEcCtD
Ketoprofen—CXCR1—GPCR downstream signaling—PTGER4—skin cancer	0.000125	0.0032	CbGpPWpGaD
Ketoprofen—Constipation—Docetaxel—skin cancer	0.000125	0.000928	CcSEcCtD
Ketoprofen—CXCL8—IL-3 Signaling Pathway—HRAS—skin cancer	0.000124	0.00318	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—SHH—skin cancer	0.000123	0.00315	CbGpPWpGaD
Ketoprofen—CXCL8—TSLP Signaling Pathway—IL6—skin cancer	0.000123	0.00314	CbGpPWpGaD
Ketoprofen—PTGS1—head—skin cancer	0.000122	0.0108	CbGeAlD
Ketoprofen—Feeling abnormal—Docetaxel—skin cancer	0.00012	0.000894	CcSEcCtD
Ketoprofen—Nausea—Fluorouracil—skin cancer	0.00012	0.000893	CcSEcCtD
Ketoprofen—Gastrointestinal pain—Docetaxel—skin cancer	0.000119	0.000887	CcSEcCtD
Ketoprofen—PTGS1—Arachidonic acid metabolism—PTGS2—skin cancer	0.000118	0.00303	CbGpPWpGaD
Ketoprofen—SLC22A8—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000118	0.00303	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—SMO—skin cancer	0.000117	0.00298	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—PTCH1—skin cancer	0.000117	0.00298	CbGpPWpGaD
Ketoprofen—SLCO1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000117	0.00298	CbGpPWpGaD
Ketoprofen—PTGS2—head—skin cancer	0.000116	0.0104	CbGeAlD
Ketoprofen—Abdominal pain—Docetaxel—skin cancer	0.000115	0.000858	CcSEcCtD
Ketoprofen—CXCR1—Signaling by GPCR—PTGER4—skin cancer	0.000113	0.00291	CbGpPWpGaD
Ketoprofen—ABCC4—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000113	0.0029	CbGpPWpGaD
Ketoprofen—PTGS2—Overview of nanoparticle effects—IL6—skin cancer	0.000111	0.00284	CbGpPWpGaD
Ketoprofen—CXCL8—GPCR ligand binding—SHH—skin cancer	0.000108	0.00277	CbGpPWpGaD
Ketoprofen—CXCL8—Spinal Cord Injury—PTGS2—skin cancer	0.000108	0.00276	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—PTCH2—skin cancer	0.000108	0.00276	CbGpPWpGaD
Ketoprofen—Hypersensitivity—Docetaxel—skin cancer	0.000108	0.0008	CcSEcCtD
Ketoprofen—CXCR1—Signaling Pathways—GLI2—skin cancer	0.000107	0.00274	CbGpPWpGaD
Ketoprofen—SLCO1A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000105	0.00269	CbGpPWpGaD
Ketoprofen—CXCL8—Cellular Senescence—CDK4—skin cancer	0.000105	0.00269	CbGpPWpGaD
Ketoprofen—Asthenia—Docetaxel—skin cancer	0.000105	0.000779	CcSEcCtD
Ketoprofen—Pruritus—Docetaxel—skin cancer	0.000103	0.000768	CcSEcCtD
Ketoprofen—CXCL8—GPCR ligand binding—SMO—skin cancer	0.000102	0.00263	CbGpPWpGaD
Ketoprofen—CXCL8—GPCR ligand binding—PTCH1—skin cancer	0.000102	0.00263	CbGpPWpGaD
Ketoprofen—CXCL8—ATF-2 transcription factor network—IL6—skin cancer	0.000102	0.00262	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—MC1R—skin cancer	0.000102	0.00261	CbGpPWpGaD
Ketoprofen—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000101	0.00259	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—GLI1—skin cancer	0.0001	0.00257	CbGpPWpGaD
Ketoprofen—CXCL8—LPA receptor mediated events—HRAS—skin cancer	0.0001	0.00257	CbGpPWpGaD
Ketoprofen—Diarrhoea—Docetaxel—skin cancer	9.99e-05	0.000742	CcSEcCtD
Ketoprofen—CXCL8—GPCR ligand binding—PTGER4—skin cancer	9.98e-05	0.00256	CbGpPWpGaD
Ketoprofen—SLC22A6—Transmembrane transport of small molecules—SLC12A2—skin cancer	9.87e-05	0.00253	CbGpPWpGaD
Ketoprofen—CXCL8—AP-1 transcription factor network—TP53—skin cancer	9.75e-05	0.0025	CbGpPWpGaD
Ketoprofen—Dizziness—Docetaxel—skin cancer	9.66e-05	0.000718	CcSEcCtD
Ketoprofen—CXCR1—Signaling Pathways—SUFU—skin cancer	9.52e-05	0.00244	CbGpPWpGaD
Ketoprofen—Vomiting—Docetaxel—skin cancer	9.29e-05	0.00069	CcSEcCtD
Ketoprofen—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	9.23e-05	0.00236	CbGpPWpGaD
Ketoprofen—Rash—Docetaxel—skin cancer	9.21e-05	0.000684	CcSEcCtD
Ketoprofen—Dermatitis—Docetaxel—skin cancer	9.2e-05	0.000684	CcSEcCtD
Ketoprofen—Headache—Docetaxel—skin cancer	9.15e-05	0.00068	CcSEcCtD
Ketoprofen—CXCL8—AP-1 transcription factor network—IL6—skin cancer	8.93e-05	0.00229	CbGpPWpGaD
Ketoprofen—PTGS1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	8.86e-05	0.00227	CbGpPWpGaD
Ketoprofen—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	8.75e-05	0.00224	CbGpPWpGaD
Ketoprofen—Nausea—Docetaxel—skin cancer	8.68e-05	0.000645	CcSEcCtD
Ketoprofen—CXCL8—Glucocorticoid receptor regulatory network—TP53—skin cancer	8.59e-05	0.0022	CbGpPWpGaD
Ketoprofen—CXCL8—GPCR downstream signaling—MC1R—skin cancer	8.58e-05	0.0022	CbGpPWpGaD
Ketoprofen—PTGS1—lymph node—skin cancer	8.51e-05	0.00759	CbGeAlD
Ketoprofen—PTGS2—lymph node—skin cancer	8.14e-05	0.00725	CbGeAlD
Ketoprofen—CXCL8—Cellular Senescence—CDKN2A—skin cancer	8.02e-05	0.00205	CbGpPWpGaD
Ketoprofen—CXCL8—Cellular responses to stress—CDK4—skin cancer	7.93e-05	0.00203	CbGpPWpGaD
Ketoprofen—CXCL8—Glucocorticoid receptor regulatory network—IL6—skin cancer	7.87e-05	0.00201	CbGpPWpGaD
Ketoprofen—PTGS2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	7.82e-05	0.002	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—MC1R—skin cancer	7.79e-05	0.00199	CbGpPWpGaD
Ketoprofen—CYP2C8—Arachidonic acid metabolism—PTGS2—skin cancer	7.65e-05	0.00196	CbGpPWpGaD
Ketoprofen—PTGS1—Selenium Micronutrient Network—PTGS2—skin cancer	7.53e-05	0.00193	CbGpPWpGaD
Ketoprofen—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	7.44e-05	0.00191	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—SHH—skin cancer	7.26e-05	0.00186	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—RASA1—skin cancer	7.22e-05	0.00185	CbGpPWpGaD
Ketoprofen—CXCL8—Senescence and Autophagy in Cancer—TP53—skin cancer	7.05e-05	0.00181	CbGpPWpGaD
Ketoprofen—PTGS2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.04e-05	0.0018	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—SMO—skin cancer	6.88e-05	0.00176	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—PTCH1—skin cancer	6.88e-05	0.00176	CbGpPWpGaD
Ketoprofen—CXCL8—Senescence and Autophagy in Cancer—HRAS—skin cancer	6.74e-05	0.00173	CbGpPWpGaD
Ketoprofen—PTGS2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	6.73e-05	0.00172	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—PTGER4—skin cancer	6.7e-05	0.00172	CbGpPWpGaD
Ketoprofen—PTGS2—C-MYB transcription factor network—CDKN2A—skin cancer	6.64e-05	0.0017	CbGpPWpGaD
Ketoprofen—PTGS2—Spinal Cord Injury—CDK4—skin cancer	6.61e-05	0.00169	CbGpPWpGaD
Ketoprofen—CXCL8—Toll-like Receptor Signaling Pathway—IL6—skin cancer	6.61e-05	0.00169	CbGpPWpGaD
Ketoprofen—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—IL6—skin cancer	6.46e-05	0.00165	CbGpPWpGaD
Ketoprofen—CXCL8—Senescence and Autophagy in Cancer—IL6—skin cancer	6.46e-05	0.00165	CbGpPWpGaD
Ketoprofen—CXCL8—Spinal Cord Injury—TP53—skin cancer	6.42e-05	0.00165	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—PTCH2—skin cancer	6.36e-05	0.00163	CbGpPWpGaD
Ketoprofen—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	6.22e-05	0.00159	CbGpPWpGaD
Ketoprofen—CXCL8—Cellular responses to stress—CDKN2A—skin cancer	6.06e-05	0.00155	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—FOXO4—skin cancer	5.92e-05	0.00152	CbGpPWpGaD
Ketoprofen—CXCL8—Spinal Cord Injury—IL6—skin cancer	5.88e-05	0.00151	CbGpPWpGaD
Ketoprofen—CYP2C8—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.73e-05	0.00147	CbGpPWpGaD
Ketoprofen—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	5.72e-05	0.00146	CbGpPWpGaD
Ketoprofen—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.69e-05	0.00146	CbGpPWpGaD
Ketoprofen—CXCL8—GPCR downstream signaling—PTGER4—skin cancer	5.64e-05	0.00144	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—SHH—skin cancer	5.55e-05	0.00142	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—PTCH1—skin cancer	5.26e-05	0.00135	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—SMO—skin cancer	5.26e-05	0.00135	CbGpPWpGaD
Ketoprofen—SLCO1A2—Metabolism—PLIN2—skin cancer	5.19e-05	0.00133	CbGpPWpGaD
Ketoprofen—CXCL8—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	5.16e-05	0.00132	CbGpPWpGaD
Ketoprofen—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.13e-05	0.00131	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—PTGER4—skin cancer	5.12e-05	0.00131	CbGpPWpGaD
Ketoprofen—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	4.84e-05	0.00124	CbGpPWpGaD
Ketoprofen—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	4.83e-05	0.00124	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—GLI2—skin cancer	4.82e-05	0.00124	CbGpPWpGaD
Ketoprofen—CXCL8—SIDS Susceptibility Pathways—IL6—skin cancer	4.7e-05	0.0012	CbGpPWpGaD
Ketoprofen—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.66e-05	0.00119	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—MC1R—skin cancer	4.6e-05	0.00118	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—GLI1—skin cancer	4.53e-05	0.00116	CbGpPWpGaD
Ketoprofen—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	4.5e-05	0.00115	CbGpPWpGaD
Ketoprofen—CXCL8—Cellular Senescence—TP53—skin cancer	4.46e-05	0.00114	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—SUFU—skin cancer	4.3e-05	0.0011	CbGpPWpGaD
Ketoprofen—SLCO1A2—Metabolism—CSPG4—skin cancer	4.18e-05	0.00107	CbGpPWpGaD
Ketoprofen—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	4.16e-05	0.00106	CbGpPWpGaD
Ketoprofen—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	4.1e-05	0.00105	CbGpPWpGaD
Ketoprofen—CXCL8—Cellular Senescence—IL6—skin cancer	4.09e-05	0.00105	CbGpPWpGaD
Ketoprofen—ALB—Vitamin B12 Metabolism—IL6—skin cancer	4.08e-05	0.00104	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—TERT—skin cancer	3.95e-05	0.00101	CbGpPWpGaD
Ketoprofen—PTGS1—Metabolism—PLIN2—skin cancer	3.95e-05	0.00101	CbGpPWpGaD
Ketoprofen—ALB—Folate Metabolism—TP53—skin cancer	3.62e-05	0.000928	CbGpPWpGaD
Ketoprofen—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	3.53e-05	0.000905	CbGpPWpGaD
Ketoprofen—CXCL8—Cellular responses to stress—TP53—skin cancer	3.37e-05	0.000864	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—NRAS—skin cancer	3.33e-05	0.000853	CbGpPWpGaD
Ketoprofen—ALB—Folate Metabolism—IL6—skin cancer	3.32e-05	0.000849	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—SHH—skin cancer	3.28e-05	0.00084	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—RASA1—skin cancer	3.26e-05	0.000834	CbGpPWpGaD
Ketoprofen—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	3.26e-05	0.000834	CbGpPWpGaD
Ketoprofen—PTGS1—Metabolism—CSPG4—skin cancer	3.18e-05	0.000815	CbGpPWpGaD
Ketoprofen—PTGS2—Metabolism—PLIN2—skin cancer	3.13e-05	0.000803	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—BRAF—skin cancer	3.13e-05	0.000802	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—SMO—skin cancer	3.11e-05	0.000796	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—PTCH1—skin cancer	3.11e-05	0.000796	CbGpPWpGaD
Ketoprofen—CXCL8—Cellular responses to stress—IL6—skin cancer	3.09e-05	0.000791	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—PTGER4—skin cancer	3.02e-05	0.000775	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—CSPG4—skin cancer	3.02e-05	0.000773	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—KRAS—skin cancer	2.87e-05	0.000734	CbGpPWpGaD
Ketoprofen—SLCO1A2—Metabolism—ENO2—skin cancer	2.84e-05	0.000728	CbGpPWpGaD
Ketoprofen—PTGS2—Spinal Cord Injury—TP53—skin cancer	2.81e-05	0.000721	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—FOXO4—skin cancer	2.67e-05	0.000684	CbGpPWpGaD
Ketoprofen—ALB—Selenium Micronutrient Network—IL6—skin cancer	2.63e-05	0.000675	CbGpPWpGaD
Ketoprofen—PTGS2—Spinal Cord Injury—IL6—skin cancer	2.58e-05	0.00066	CbGpPWpGaD
Ketoprofen—CYP2C8—Metabolism—PLIN2—skin cancer	2.55e-05	0.000653	CbGpPWpGaD
Ketoprofen—ALB—Metabolism—PLIN2—skin cancer	2.54e-05	0.000649	CbGpPWpGaD
Ketoprofen—PTGS2—Metabolism—CSPG4—skin cancer	2.53e-05	0.000647	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—HRAS—skin cancer	2.44e-05	0.000624	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling by GPCR—IL6—skin cancer	2.33e-05	0.000597	CbGpPWpGaD
Ketoprofen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.22e-05	0.00057	CbGpPWpGaD
Ketoprofen—PTGS1—Metabolism—ENO2—skin cancer	2.16e-05	0.000554	CbGpPWpGaD
Ketoprofen—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.15e-05	0.000552	CbGpPWpGaD
Ketoprofen—CYP2C9—Metabolism—PLIN2—skin cancer	2.08e-05	0.000532	CbGpPWpGaD
Ketoprofen—CYP2C8—Metabolism—CSPG4—skin cancer	2.06e-05	0.000526	CbGpPWpGaD
Ketoprofen—ABCC4—Hemostasis—NRAS—skin cancer	2.05e-05	0.000526	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—ENO2—skin cancer	2.05e-05	0.000525	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—SHH—skin cancer	2.05e-05	0.000525	CbGpPWpGaD
Ketoprofen—ALB—Metabolism—CSPG4—skin cancer	2.04e-05	0.000523	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—NRAS—skin cancer	1.97e-05	0.000504	CbGpPWpGaD
Ketoprofen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.91e-05	0.00049	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—TERT—skin cancer	1.78e-05	0.000457	CbGpPWpGaD
Ketoprofen—ABCC4—Hemostasis—KRAS—skin cancer	1.77e-05	0.000452	CbGpPWpGaD
Ketoprofen—PTGS2—Metabolism—ENO2—skin cancer	1.72e-05	0.00044	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—KRAS—skin cancer	1.69e-05	0.000434	CbGpPWpGaD
Ketoprofen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.69e-05	0.000433	CbGpPWpGaD
Ketoprofen—CYP2C9—Metabolism—CSPG4—skin cancer	1.67e-05	0.000428	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—FOXO4—skin cancer	1.67e-05	0.000428	CbGpPWpGaD
Ketoprofen—SLCO1A2—Metabolism—ERCC2—skin cancer	1.65e-05	0.000423	CbGpPWpGaD
Ketoprofen—ABCC4—Hemostasis—TP53—skin cancer	1.57e-05	0.000402	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—TP53—skin cancer	1.51e-05	0.000386	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—NRAS—skin cancer	1.5e-05	0.000385	CbGpPWpGaD
Ketoprofen—ABCC4—Hemostasis—HRAS—skin cancer	1.5e-05	0.000384	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—HRAS—skin cancer	1.44e-05	0.000369	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—BRAF—skin cancer	1.41e-05	0.000362	CbGpPWpGaD
Ketoprofen—CYP2C8—Metabolism—ENO2—skin cancer	1.4e-05	0.000358	CbGpPWpGaD
Ketoprofen—ALB—Metabolism—ENO2—skin cancer	1.39e-05	0.000356	CbGpPWpGaD
Ketoprofen—CXCR1—Signaling Pathways—IL6—skin cancer	1.38e-05	0.000353	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—KRAS—skin cancer	1.29e-05	0.000331	CbGpPWpGaD
Ketoprofen—PTGS1—Metabolism—ERCC2—skin cancer	1.26e-05	0.000322	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—ERCC2—skin cancer	1.19e-05	0.000305	CbGpPWpGaD
Ketoprofen—CYP2C9—Metabolism—ENO2—skin cancer	1.14e-05	0.000291	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—TERT—skin cancer	1.12e-05	0.000286	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—HRAS—skin cancer	1.1e-05	0.000282	CbGpPWpGaD
Ketoprofen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.09e-05	0.00028	CbGpPWpGaD
Ketoprofen—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.09e-05	0.000278	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling by GPCR—IL6—skin cancer	1.05e-05	0.00027	CbGpPWpGaD
Ketoprofen—PTGS2—Metabolism—ERCC2—skin cancer	9.97e-06	0.000255	CbGpPWpGaD
Ketoprofen—SLCO1A2—Metabolism—PTGS2—skin cancer	9.9e-06	0.000254	CbGpPWpGaD
Ketoprofen—ALB—Hemostasis—NRAS—skin cancer	9.29e-06	0.000238	CbGpPWpGaD
Ketoprofen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.89e-06	0.000228	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—NRAS—skin cancer	8.88e-06	0.000227	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—BRAF—skin cancer	8.84e-06	0.000226	CbGpPWpGaD
Ketoprofen—CYP2C8—Metabolism—ERCC2—skin cancer	8.12e-06	0.000208	CbGpPWpGaD
Ketoprofen—ALB—Metabolism—ERCC2—skin cancer	8.07e-06	0.000207	CbGpPWpGaD
Ketoprofen—ALB—Hemostasis—KRAS—skin cancer	7.99e-06	0.000205	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—KRAS—skin cancer	7.65e-06	0.000196	CbGpPWpGaD
Ketoprofen—PTGS1—Metabolism—PTGS2—skin cancer	7.53e-06	0.000193	CbGpPWpGaD
Ketoprofen—ALB—Hemostasis—TP53—skin cancer	7.1e-06	0.000182	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—TP53—skin cancer	6.79e-06	0.000174	CbGpPWpGaD
Ketoprofen—ALB—Hemostasis—HRAS—skin cancer	6.79e-06	0.000174	CbGpPWpGaD
Ketoprofen—CYP2C9—Metabolism—ERCC2—skin cancer	6.61e-06	0.000169	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—HRAS—skin cancer	6.5e-06	0.000166	CbGpPWpGaD
Ketoprofen—CXCL8—Signaling Pathways—IL6—skin cancer	6.22e-06	0.000159	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—NRAS—skin cancer	5.56e-06	0.000142	CbGpPWpGaD
Ketoprofen—CYP2C8—Metabolism—PTGS2—skin cancer	4.87e-06	0.000125	CbGpPWpGaD
Ketoprofen—ALB—Metabolism—PTGS2—skin cancer	4.84e-06	0.000124	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—KRAS—skin cancer	4.78e-06	0.000122	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—HRAS—skin cancer	4.06e-06	0.000104	CbGpPWpGaD
Ketoprofen—CYP2C9—Metabolism—PTGS2—skin cancer	3.96e-06	0.000101	CbGpPWpGaD
Ketoprofen—PTGS2—Disease—IL6—skin cancer	3.89e-06	9.96e-05	CbGpPWpGaD
